Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Investors' Reports
NEW YORK, September 12, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Investors' Reports announced new research reports highlighting Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), Oncolytics Biotech, Inc. (NASDAQ: ONCY), Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK), Sangamo BioSciences, Inc. (NASDAQ: SGMO), and PDL BioPharma, Inc. (NASDAQ: PDLI). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Aegerion Pharmaceuticals, Inc. Research Report
On September 8, 2013, Aegerion Pharmaceuticals, Inc. (Aegerion) announced that it has received orphan drug designation from Japan's Ministry of Labour, Health and Welfare for lomitapide which is used in the treatment of homozygous familial hypercholesterolemia (HoFH). The Company informed that it is currently conducting a pharmacokinetic/pharmacodynamics (PK/PD) study of lomitapide required by the Japanese regulatory authorities and expects the study to be completed in Q4 2013. Post the completion of the study, the Company also plans to conduct a small therapeutic study of lomitapide in Japanese adult HoFH patients. The Full Research Report on Aegerion Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-09/AEGR]
Oncolytics Biotech, Inc. Research Report
On September 9, 2013, Oncolytics Biotech, Inc. (Oncolytics) announced final tumour response data from its US Phase 2 single arm clinical trial in patients with squamous cell carcinoma of the lung (SCCLC) using intravenous administration of REOLYSIN in combination with carboplatin and paclitaxel (REO 021). Oncolytics stated that the study enrolled patients with metastatic stage IIIB or stage IV, or recurrent, squamous cell carcinoma of the lung, who were chemotherapy-naïve for their metastatic or recurrent cancer. According to Oncolytics, the analysis examined percent best overall tumour responses between pre-treatment and up to six treatment cycles and revealed that out of 25 evaluable patients who had more than one cycle of therapy, 92% exhibited overall tumour shrinkage. Oncolytics also informed that final progression-free survival and safety data for the study will be reported in late 2013. The Full Research Report on Oncolytics Biotech, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-09/ONCY]
Merrimack Pharmaceuticals, Inc. Research Report
On August 28, 2013, Merrimack Pharmaceuticals, Inc. (Merrimack) announced that it has reached its enrollment goal in the NAPOLI-1 trial, a randomized Phase 3 study of MM-398, with or without 5-fluorouracil (5-FU) and leucovorin (LV), versus 5-FU and LV, in patients with metastatic pancreatic cancer previously treated with gemcitabine-based therapy. Eliel Bayever, M.D., Vice President of Merrimack and Medical Director of MM-398 said, "To our knowledge this is one of the largest controlled studies ever conducted in this patient population, which has very few treatment options." The Full Research Report on Merrimack Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-09/MACK]
Sangamo BioSciences, Inc. Research Report
On August 26, 2013, Sangamo BioSciences, Inc. (Sangamo) announced that it has signed a definitive agreement to acquire Ceregene, Inc. (Ceregene), a privately held biotechnology company focused on developing adeno-associated virus (AAV) gene therapies.The Company informed that in accordance with the terms of the agreement, Sangamo will issue to the stockholders of Ceregene 100,000 shares of Sangamo's common stock, representing less than 0.2% of Sangamo's total shares outstanding. Further, the Company has agreed to make contingent earn-out payments to the stockholders of Ceregene based upon revenues generated from license or sales transaction of certain existing products of Ceregene. Sangamo expects the acquisition to close in September 2013, and does not expect it to have any impact on the Company's financial guidance for full-year 2013 operating expenses or year-end cash balance. The Full Research Report on Sangamo BioSciences, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-09/SGMO]
PDL BioPharma, Inc. Research Report
On September 9, 2013, PDL BioPharma, Inc. (PDL) announced revenue guidance for Q3 2013. The Company expects revenues of approximately $97 million, as compared with revenues of $85 million reported in Q3 2012, representing an increase of 14.1% YoY. The Company informed that its revenue guidance is driven by increased Q2 2013 sales for Avastin, Herceptin, Lucentis, Xolair, Kadcyla, Perjeta, and Actemra, for which PDL receives royalties in Q3 2013. The Full Research Report on PDL BioPharma, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-09/PDLI]
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
©2012 PR Newswire. All Rights Reserved.